Q32 Bio Inc. (QTTB) Financial Statements (2025 and earlier)

Company Profile

Business Address 830 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments77,96582,653175,026155,873217,431262,388
Cash and cash equivalent77,96539,26633,986108,382217,43153,774
Short-term investments  43,387141,04047,491 208,614
Prepaid expense885     
Other current assets396     
Other undisclosed current assets2,6311,2615,98936,0362,1334,189
Total current assets:81,87783,914181,015191,909219,564266,577
Noncurrent Assets
Operating lease, right-of-use asset5,72265020,56315,6075,897 
Property, plant and equipment1,370 1,0782,25237,00242,716
Long-term investments and receivables   25,800   
Long-term investments   25,800   
Restricted cash and investments647     
Other noncurrent assets116     
Other undisclosed noncurrent assets 2,600 141,9531,2741,274
Total noncurrent assets:10,45565047,45519,81244,17343,990
TOTAL ASSETS:92,33284,564228,470211,721263,737310,567
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,46810,25510,41211,57912,1197,957
Employee-related liabilities7,8056,9024,551
Accounts payable2,9893,2341,1442,3664,7222,608
Accrued liabilities7,4797,0219,2681,408495798
Deferred revenue   1,1563,2085,632809
Debt3,097     
Deferred compensation liability   800   
Deferred rent credit      1,313
Other undisclosed current liabilities 2,9001,31810,2082,4394,9072,295
Total current liabilities:16,46511,57322,57617,22622,65812,374
Noncurrent Liabilities
Long-term debt and lease obligation9,556  23,68812,941 
Long-term debt, excluding current maturities9,556     
Liabilities, other than long-term debt60,636 27,9161,15632,14339,686
Deferred revenue    1,15632,14330,142
Deferred rent credit      9,544
Other liabilities55,000     
Operating lease, liability5,636 27,91623,68812,941 
Total noncurrent liabilities:70,192 27,91624,84445,08439,686
Total liabilities:86,65711,57350,49242,07067,74252,060
Equity
Equity, attributable to parent5,67572,991177,978169,651195,995258,507
Common stock266654
Additional paid in capital240,487615,088607,513593,784524,358457,994
Accumulated other comprehensive income (loss)  (5)(404)(7) 183
Accumulated deficit(234,814)(542,098)(429,137)(424,132)(328,368)(199,674)
Total equity:5,67572,991177,978169,651195,995258,507
TOTAL LIABILITIES AND EQUITY:92,33284,564228,470211,721263,737310,567

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues  2,3123,20833,9712,7021,666
Amortization of lease incentives6,320  
Sublease income  2,3121,979861913 
Gross profit:  2,3123,20833,9712,7021,666
Operating expenses(66,102)(102,585)(136,489)(129,920)(132,965)(111,609)
Other operating expense, net
(Other undisclosed Other operating expense, net)
      
Other undisclosed operating income (loss) (1,156)    
Operating loss:(66,102)(101,429)(133,281)(95,949)(130,263)(109,943)
Nonoperating income20,01514,349134,4793703,1386,027
Investment income, nonoperating    1851,569 
Other nonoperating income4,12514,349134,4791851,5696,027
Income (loss) from continuing operations before equity method investments, income taxes:(46,087)(87,080)1,198(95,579)(127,125)(103,916)
Loss from equity method investments (1,625)     
Income (loss) from continuing operations before income taxes:(47,712)(87,080)1,198(95,579)(127,125)(103,916)
Income tax expense (21) (715)   
Other undisclosed loss from continuing operations      
Income (loss) from continuing operations:(47,733)(87,080)483(95,579)(127,125)(103,916)
Loss before gain (loss) on sale of properties:(95,579)(127,125)(103,916)
Other undisclosed net loss  (25,881)(5,488)(185)(1,569) 
Net loss attributable to parent:(47,733)(112,961)(5,005)(95,764)(128,694)(103,916)
Other undisclosed net income available to common stockholders, basic47,685     
Net loss available to common stockholders, basic:(48)(112,961)(5,005)(95,764)(128,694)(103,916)
Other undisclosed net income (loss) available to common stockholders, diluted(16)     
Net income (loss) available to common stockholders, diluted:(64)(112,961)(5,005)(95,764)(128,694)(103,916)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(47,733)(112,961)(5,005)(95,764)(128,694)(103,916)
Comprehensive loss:(47,733)(112,961)(5,005)(95,764)(128,694)(103,916)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 399(397)(7)(183)260
Comprehensive loss, net of tax, attributable to parent:(47,733)(112,562)(5,402)(95,771)(128,877)(103,656)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: